NCT01202279

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Mucinex D for Symptomatic Therapy in Patients With Acute Upper Respiratory Tract Who Seek Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,179 (actual)
• Sponsor: Reckitt Benckiser Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo

Conditions

• Acute Upper Respiratory Track Infection

Interventions

Type	Name	Description
DRUG	Guaifenesin	1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
DEVICE	Placebo	Placebo bid for 7 days

Timeline

• Start date: 2009-10-01
• Primary completion: 2010-04-01
• Completion: 2010-07-01
• First posted: 2010-09-15
• Last updated: 2020-12-30
• Results posted: 2012-11-05

Locations

24 sites across 1 country: United States